| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JBM.B.31289 |
| P8608 | Fatcat ID | release_jsoq4myrznd7rczglgolqak5wi |
| P932 | PMC publication ID | 2775925 |
| P698 | PubMed publication ID | 19072988 |
| P5875 | ResearchGate publication ID | 227757346 |
| P2093 | author name string | Lori A Setton | |
| Mohammed F Shamji | |||
| Samuel B Adams | |||
| Dana L Nettles | |||
| Priscilla Hwang | |||
| Robert W Bullock | |||
| P2860 | cites work | Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease | Q24247745 |
| Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonist | Q24656182 | ||
| A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity | Q24675629 | ||
| A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab | Q28282330 | ||
| Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy | Q33282319 | ||
| Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions | Q33956003 | ||
| Application of chitosan-based polysaccharide biomaterials in cartilage tissue engineering: a review | Q34079431 | ||
| Responsive polymeric delivery systems. | Q34190334 | ||
| Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis. | Q34383275 | ||
| Hydrogels for biomedical applications | Q34469979 | ||
| Infliximab and ulcerative colitis. | Q34503548 | ||
| Clinical studies with curcumin | Q34637583 | ||
| Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic | Q34707694 | ||
| Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases | Q35538349 | ||
| Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. | Q35554464 | ||
| Anti-TNF therapy in Crohn's disease | Q36019663 | ||
| Stimuli responsive polymers for biomedical applications. | Q36052138 | ||
| Safety of biologic therapies--an update | Q36059518 | ||
| Why does tumor necrosis factor targeted therapy reactivate tuberculosis? | Q36059536 | ||
| Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. | Q36059540 | ||
| Beneficial role of curcumin in skin diseases | Q36849509 | ||
| Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis | Q37011980 | ||
| Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. | Q37125494 | ||
| Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. | Q37628836 | ||
| When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents | Q40126097 | ||
| ReGel polymer-based delivery of interleukin-2 as a cancer treatment | Q40232201 | ||
| Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery | Q40374638 | ||
| Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. | Q40397492 | ||
| Cytotoxicity of thermosensitive polymers poly(N-isopropylacrylamide), poly(N-vinylcaprolactam) and amphiphilically modified poly(N-vinylcaprolactam). | Q40480132 | ||
| A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel | Q40598548 | ||
| Novel injectable neutral solutions of chitosan form biodegradable gels in situ | Q42696202 | ||
| In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride | Q43768872 | ||
| Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials | Q44023804 | ||
| Percutaneous absorption of non-steroidal anti-inflammatory drugs from in situ gelling xyloglucan formulations in rats | Q44149133 | ||
| Biodegradable microspheres of curcumin for treatment of inflammation. | Q44261365 | ||
| Self-assembled supramolecular hydrogels formed by biodegradable PEO-PHB-PEO triblock copolymers and alpha-cyclodextrin for controlled drug delivery | Q44710291 | ||
| Biodegradable block copolymers for delivery of proteins and water-insoluble drugs | Q44748796 | ||
| Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints. | Q45026618 | ||
| Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation | Q46766148 | ||
| Thermo-sensitive and biodegradable hydrogels based on stereocomplexed Pluronic multi-block copolymers for controlled protein delivery | Q46782631 | ||
| Ionization and solubility of chitosan solutions related to thermosensitive chitosan/glycerol-phosphate systems. | Q50914140 | ||
| Etanercept for Crohn's disease. | Q51029112 | ||
| Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. | Q51117743 | ||
| Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance | Q57995793 | ||
| Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with99mTc-infliximab | Q59577679 | ||
| Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats | Q67976744 | ||
| Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice | Q68177118 | ||
| Sustained-release of urease from a poloxamer gel matrix | Q68782245 | ||
| Effects of chitosan on rat knee cartilages | Q73065793 | ||
| Bone morphogenetic protein excipients: comparative observations on poloxamer | Q73498254 | ||
| Characterization of thermosensitive chitosan gels for the sustained delivery of drugs | Q74249190 | ||
| Poloxamer 407-induced atherogenesis in the C57BL/6 mouse | Q74449529 | ||
| Thermally reversible xyloglucan gels as vehicles for rectal drug delivery | Q77509101 | ||
| P433 | issue | 1 | |
| P921 | main subject | drug delivery | Q1392806 |
| P304 | page(s) | 319-326 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Journal of Biomedical Materials Research Part B | Q6294852 |
| P1476 | title | Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery | |
| P478 | volume | 90 |
| Q51251797 | Characterization and cytocompatibility of thermosensitive hydrogel embedded with chitosan nanoparticles for delivery of bone morphogenetic protein-2 plasmid DNA. |
| Q38700498 | Delivery strategies to control inflammatory response: Modulating M1-M2 polarization in tissue engineering applications. |
| Q47125223 | Effects of Inflammation on Multiscale Biomechanical Properties of Cartilaginous Cells and Tissues |
| Q26850868 | Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines |
| Q96951726 | Engineering immunomodulatory biomaterials for type 1 diabetes |
| Q36307467 | Nano-enabled delivery of diverse payloads across complex biological barriers |
| Q61813444 | Nanostructured Chitosan-Based Biomaterials for Sustained and Colon-Specific Resveratrol Release |
| Q57371737 | Synthesis, Characterization and Properties of a Physically and Chemically Gelling Polymer System Using Poly(NIPAAm-co-HEMA-acrylate) and Poly(NIPAAm-co-cysteamine) |
| Q38168579 | Thermosensitive chitosan/glycerophosphate-based hydrogel and its derivatives in pharmaceutical and biomedical applications |
Search more.